Stock Research for ALNY


Featured Broker: Ally Invest

Get the due diligence for another stock.


ALNY Stock Chart & Research Data

The ALNY chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ALNY chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


ALNY Due diligence Resources & Stock Charts

The ALNY stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ALNY Detailed Price Forecast - CNN Money CNN View ALNY Detailed Summary - Google Finance
Yahoo View ALNY Detailed Summary - Yahoo! Finance Zacks View ALNY Stock Research & Analysis -

Stock Analysis

TradeIdeas View ALNY Trends & Analysis - Trade-Ideas Barrons View ALNY Major Holders - Barrons
NASDAQ View ALNY Call Transcripts - NASDAQ Seeking View ALNY Breaking News & Analysis - Seeking Alpha
Spotlight View ALNY Annual Report - OTC Report View ALNY OTC Short Report -
TradeKing View ALNY Fundamentals - TradeKing Charts View ALNY SEC Filings - Bar Chart
WSJ View Historical Prices for ALNY - The WSJ Morningstar View Performance/Total Return for ALNY - Morningstar
MarketWatch View the Analyst Estimates for ALNY - MarketWatch CNBC View the Earnings History for ALNY - CNBC
StockMarketWatch View the ALNY Earnings - StockMarketWatch MacroAxis View ALNY Buy or Sell Recommendations - MacroAxis
Bullish View the ALNY Bullish Patterns - American Bulls Short Pains View ALNY Short Pain Metrics -

Social Media Mentions

StockTwits View ALNY Stock Mentions - StockTwits PennyStocks View ALNY Stock Mentions - PennyStockTweets
Twitter View ALNY Stock Mentions - Twitter Invest Hub View ALNY Investment Forum News - Investor Hub
Yahoo View ALNY Stock Mentions - Yahoo! Message Board Seeking Alpha View ALNY Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for ALNY - Insider Cow View Insider Transactions for ALNY - Insider Cow
CNBC View ALNY Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ALNY - OTC Markets
Yahoo View Insider Transactions for ALNY - Yahoo! Finance NASDAQ View Institutional Holdings for ALNY - NASDAQ

Stock Charts

FinViz View ALNY Stock Insight & Charts - StockCharts View ALNY Investment Charts -
BarChart View ALNY Stock Overview & Charts - BarChart Trading View View ALNY User Generated Charts - Trading View

Latest Financial News for ALNY

Alnylam to Host Fifth Annual “RNAi Roundtable” Webcast Series
Posted on Thursday June 21, 2018

Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 5th annual series of “RNAi Roundtable” webcasts this summer. The 2018 series will offer a range of presentations from Alnylam scientists, clinical collaborators, and patients or patient advocates, who will review recent progress in many of the Company’s late-stage pipeline programs and platform.

Caladrius Biosciences’ Stock Price Rose 67% on June 19
Posted on Wednesday June 20, 2018

On June 19, Caladrius Biosciences’ stock price rose 67.3% and reached $6.61 from the previous close of $3.95 on June 18.

Alnylam Expands Senior Leadership Team with Two Key Appointments
Posted on Wednesday June 20, 2018

Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today the appointments of two accomplished biotech executives, Masako Nakamura as Senior Vice President, Head of Asia, and Jing L. Marantz, M.D., Ph.D., as Senior Vice President, Head of Medical Affairs. "We are pleased to have Masako and Jing join us at an exciting crossroads in Alnylam’s journey from an R&D to a commercial organization.

Alnylam to Report New Clinical Results for Patisiran at the 4th Congress of the European Academy of Neurology
Posted on Friday June 15, 2018

Alnylam Pharmaceuticals, Inc.  , the leading RNAi therapeutics company, today announced that additional results from the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic for the treatment of hereditary ATTR amyloidosis, will be presented at the 4th Congress of the European Academy of Neurology , being held June 16-19, 2018 in Lisbon, Portugal.

Enter a stock symbol to view the stock details.